WC
PRME icon

Wexford Capital’s Prime Medicine PRME Stock Holding History

Wexford Capital’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-153,705
Closed -$1.89M – 241
2023
Q1 		$1.89M Buy
+153,705
New +$2.5M 0.39% 53

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Wexford Capital's PRME Position: Q2 2023 in Review

Wexford Capital sold out of Prime Medicine (PRME) in Q2 2023, closing a stake of 153,705 shares — an estimated $1.89M sold.

Wexford Capital first reported a position in PRME in Q1 2023 and held it in 1 quarter. The position peaked at $1.89M in Q1 2023. 79 funds tracked by Wall St. Rank hold PRME as of Q2 2023.

  • Wexford Capital reported no remaining Prime Medicine position as of Q2 2023 after selling out during the quarter.
  • Wexford Capital sold 153,705 Prime Medicine shares in Q2 2023, an estimated $1.89M.
  • Wexford Capital first reported a position in Prime Medicine in Q1 2023 and held it in 1 quarter.
  • Wexford Capital's Prime Medicine position peaked at $1.89M in Q1 2023.
  • 79 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2023.

Based on Wexford Capital's 13F filing for Q2 2023, filed 14 Aug 2023.